European Commission Scrutinizes Google’s Site Reputation Abuse Policy

by THEFUTURE.TEAM

November 13, 2025

The European Commission has initiated a comprehensive investigation into Google’s site reputation abuse policy and its impact on digital publishers across Europe.

Concerns Over Algorithmic Influence

The commission’s probe comes after it observed that Google may be relegating news media and other publisher websites lower in search rankings when they feature content from their business partners. Authorities contend that such measures compromise publishers’ ability to monetize their platforms, potentially stifling innovation and restricting legitimate business practices.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Reassessing Anti-Spam Measures

Google maintains that its policy is vital in curbing deceptive practices. The company’s official page outlines how the measures are designed to prevent websites from manipulating search rankings by republishing third-party content. Pandu Nayak, Google’s Chief Scientist of Search, argued in a recent blog post that the investigation is misguided, noting that a German court previously affirmed the policy as valid, reasonable, and consistently applied in the fight against spam and pay-for-play tactics.

Potential Regulatory Repercussions

The stakes are high. Should the investigation reveal that Google’s practices violate the European Union’s Digital Markets Act, the Commission could impose fines reaching up to 10% of Alphabet’s global annual turnover. A systematic infringement might also prompt measures such as forced divestitures or constraints on future acquisitions, serving as a stern warning to major industry players.

Heightened Scrutiny of Big Tech

Designated as a “core platform service” under the DMA in 2023, Google Search is already under separate scrutiny for allegedly favoring its own services. The current investigation into its site reputation abuse policy further underscores the European Commission’s resolve to enforce fair competition and ensure digital market integrity across the tech sector.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Breaking news